Format

Send to

Choose Destination
Oncology (Williston Park). 2005 Jul;19(8):1077-84; discussion 1084, 1087-8.

Thromboembolic complications of malignancy. Part 2: management.

Author information

1
Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington, USA. linen@u.washington.edu

Abstract

Thromboembolism affects many patients with solid tumors and clonal hematologic malignancies. Thromboprophylaxis with low-molecular-weight heparin (LMWH) is indicated for surgery and other high-risk situations, but not routinely for central venous catheters or nonsurgical, ambulatory management. Thrombotic events require full anticoagulation for the duration of active disease and/or the prothrombotic stimulus. LMWHs are safe and more effective than both unfractionated heparin for initial therapy and warfarin for secondary prevention. Anti-inflammatory and antiangiogenic properties might account for this advantage and for a survival benefit of chronic LMWH in subgroups of cancer patients. Ongoing studies are characterizing the cost-effectiveness and antitumor mechanisms of LMWHs, the potential utility of newer anticoagulants, and the ability of predictive models to identify high-risk candidates for thromboprophylaxis.

PMID:
16131048
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for UBM Medica LLC
Loading ...
Support Center